share_log

Results: Intuitive Surgical, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Results: Intuitive Surgical, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

业绩:Intuitive Surgical, Inc. 超出盈利预期,分析师现在有了新的预测
Simply Wall St ·  04/20 08:36

Shareholders might have noticed that Intuitive Surgical, Inc. (NASDAQ:ISRG) filed its first-quarter result this time last week. The early response was not positive, with shares down 4.8% to US$366 in the past week. Revenues were US$1.9b, approximately in line with whatthe analysts expected, although statutory earnings per share (EPS) crushed expectations, coming in at US$1.51, an impressive 29% ahead of estimates. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

股东们可能已经注意到,Intuitive Surgical, Inc.(纳斯达克股票代码:ISRG)上周这个时候公布了第一季度业绩。早期的反应并不乐观,过去一周股价下跌4.8%,至366美元。收入为19亿美元,与分析师的预期大致一致,尽管法定每股收益(EPS)打破了预期,为1.51美元,比预期高出29%,令人印象深刻。根据结果,分析师更新了他们的盈利模式,很高兴知道他们是否认为公司的前景发生了巨大变化,或者业务是否照旧。根据这些结果,我们收集了最新的法定预测,以了解分析师是否改变了盈利模式。

earnings-and-revenue-growth
NasdaqGS:ISRG Earnings and Revenue Growth April 20th 2024
NASDAQGS: ISRG 收益和收入增长 2024 年 4 月 20 日

Following the latest results, Intuitive Surgical's 28 analysts are now forecasting revenues of US$8.02b in 2024. This would be a meaningful 9.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are forecast to decrease 4.3% to US$5.36 in the same period. In the lead-up to this report, the analysts had been modelling revenues of US$8.00b and earnings per share (EPS) of US$5.14 in 2024. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.

根据最新业绩,Intuitive Surgical的28位分析师现在预测2024年的收入为80.2亿美元。与过去12个月相比,这将使收入显著增长9.6%。预计同期法定每股收益将下降4.3%,至5.36美元。在本报告发布之前,分析师一直在模拟2024年的收入为800亿美元,每股收益(EPS)为5.14美元。从他们新的每股收益估计来看,分析师似乎对该业务更加看好。

There's been no major changes to the consensus price target of US$419, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Intuitive Surgical analyst has a price target of US$475 per share, while the most pessimistic values it at US$253. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

419美元的共识目标股价没有重大变化,这表明每股收益前景的改善不足以对该股估值产生长期的积极影响。但是,固定单一价格目标可能是不明智的,因为共识目标实际上是分析师目标股价的平均值。因此,一些投资者喜欢查看估计范围,看看对公司的估值是否有任何分歧。最乐观的Intuitive Surgical分析师将目标股价定为每股475美元,而最悲观的分析师则将其目标股价定为253美元。对该股肯定有一些不同的看法,但在我们看来,估计范围还不够广,不足以暗示情况不可预测。

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The period to the end of 2024 brings more of the same, according to the analysts, with revenue forecast to display 13% growth on an annualised basis. That is in line with its 13% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 8.0% per year. So it's pretty clear that Intuitive Surgical is forecast to grow substantially faster than its industry.

了解这些预测的更多背景信息的一种方法是研究它们与过去的业绩相比如何,以及同一行业中其他公司的表现。分析师表示,截至2024年底将带来更多相同的情况,收入按年计算预计将增长13%。这与其在过去五年中13%的年增长率一致。相比之下,我们的数据表明,预计类似行业的其他公司(有分析师报道)的收入每年将增长8.0%。因此,很明显,预计Intuitive Surgical的增长速度将大大快于其行业。

The Bottom Line

底线

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Intuitive Surgical's earnings potential next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at US$419, with the latest estimates not enough to have an impact on their price targets.

对我们来说,最大的收获是共识的每股收益上调,这表明人们对Intuitive Surgical明年盈利潜力的看法明显改善。令人高兴的是,收入预测没有重大变化,预计该业务的增长速度仍将快于整个行业。共识目标股价稳定在419美元,最新估计不足以对其目标价格产生影响。

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Intuitive Surgical going out to 2026, and you can see them free on our platform here..

话虽如此,公司收益的长期轨迹比明年重要得多。在Simply Wall St,我们有分析师对到2026年的Intuitive Surgical的全方位估计,你可以在我们的平台上免费查看。

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

需要考虑的另一件事是管理层和董事最近是否在买入或卖出股票。我们在此处概述了过去十二个月在我们的平台上所有公开市场股票交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发